Efficacy of endoxifen, a protein kinase C inhibitor for acute and mixed mania: Some concerns worth considering
- PMID: 34214241
- DOI: 10.1111/bdi.13109
Efficacy of endoxifen, a protein kinase C inhibitor for acute and mixed mania: Some concerns worth considering
Comment in
-
Reply to Ghosh et al1 . Comments on Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder.Bipolar Disord. 2022 Feb;24(1):91-92. doi: 10.1111/bdi.13151. Epub 2021 Nov 23. Bipolar Disord. 2022. PMID: 34773320 No abstract available.
Comment on
-
Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder.Bipolar Disord. 2021 Sep;23(6):595-603. doi: 10.1111/bdi.13041. Epub 2021 Jan 9. Bipolar Disord. 2021. PMID: 33368969 Clinical Trial.
References
REFERENCES
-
- Ahmad A, Sheikh S, Khan MA, et al. Endoxifen: a new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord. 2020. https://doi.org/10.1111/BDI.13041
-
- Harden M, Friede T. Sample size calculation in multi-centre clinical trials. BMC Med Res Methodol. 2018;18(1):156. https://doi.org/10.1186/s12874-018-0602-y
-
- Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145:62-69.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical